Clinical Neurology: Research Article

Yao T.a· Qiao H.b· Sun J.c· Li X.a· Song Y.d· Xu F.d· Gao L.c· Zhang D.c· Yan Z.e· Ye C.f· Lai H.d· Liang Z.g· Wu T.c· Wang C.a

Author affiliations

aDepartment of Neurology, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Disorders, Beijing, China
bDepartment of Nuclear Medicine, Xuanwu Hospital of Capital Medical University, Beijing, China
cDepartment of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics, Beijing, China
dDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China
eSchool of Electronic and Information Engineering, Harbin Institute of Technology at Shenzhen, Shenzhen, China
fPengCheng Laboratory, Shenzhen, China
gDepartment of Nuclear Medicine, Information Center Xuanwu Hospital of Capital Medical University, Beijing, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: December 08, 2021
Accepted: May 18, 2022
Published online: July 19, 2022

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Abstract

Background: Spinocerebellar ataxia type 12 (SCA12) is a rare SCA subtype with unclear clinical and imaging features. Also, the radiological changes in prodromal and early stages remain unknown. Methods: Ten symptomatic and two pre­symptomatic cases from three Chinese pedigrees received clinical assessments and imaging studies including routine magnetic resonance imaging (MRI), diffusion kurtosis imaging (DKI), and positron emission tomography (PET) using 18F-flurodeoxyglucose (FDG) to investigate glucose metabolism in brain and 18F-vesicle monoamine transporter 2 (VMAT2) to inspect the integrity of the dopaminergic neuron. Seventy-two healthy individuals were recruited as controls in the quantitative FDG-PET analysis. Imaging parameters were compared between symptomatic and presymptomatic cases with different disease durations. Results: Patients displayed prominent action tremor, moderate ataxia, and subtle parkinsonism with poor levodopa-response. MRI showed extensive but heterogeneous cerebral atrophy, which was most evident in the frontoparietal lobes. Cerebellar atrophy was apparent in later stages. DKI detected impaired fibers in the cerebellar peduncles. In both symptomatic and pre­symptomatic cases, PET-CT showed an earlier FDG decline than atrophic changes in multiple regions, and the frontoparietal lobes were the earliest and most severe. However, the VMAT2 density were normal in the putamen and caudate nucleus of most cases (7/8). Conclusions: We first found that hypometabolism in the cerebral cortex, but not cerebellum, is an early and prominent change in SCA12. The integrity of presynaptic dopaminergic neurons remains largely spared during the whole disease process.

© 2022 S. Karger AG, Basel

References Holmes SE, O’Hearn EE, McInnis MG, Gorelick-Feldman DA, Kleiderlein JJ, Callahan C, et al. Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with SCA12. Nat Genet. 1999 Dec;23(4):391–2. Bahl S, Virdi K, Mittal U, Sachdeva MP, Kalla AK, Holmes SE, et al. Evidence of a common founder for SCA12 in the Indian population. Ann Hum Genet. 2005 Sep;69(Pt 5):528–34. Srivastava AK, Choudhry S, Gopinath MS, Roy S, Tripathi M, Brahmachari SK, et al. Molecular and clinical correlation in five Indian families with spinocerebellar ataxia 12. Ann Neurol. 2001 Dec;50(6):796–800. Cohen RL, Margolis RL. Spinocerebellar ataxia type 12: clues to pathogenesis. Curr Opin Neurol. 2016 Dec;29(6):735–42. Choudhury S, Chatterjee S, Chatterjee K, Banerjee R, Humby J, Mondal B, et al. Clinical characterization of genetically diagnosed cases of spinocerebellar ataxia type 12 from India. Mov Disord Clin Pract. 2017 Nov 1;5(1):39–46. Srivastava AK, Takkar A, Garg A, Faruq M. Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B. Brain. 2017 Jan;140(1):27–36. Hu T, Zhao B, Wei QQ, Shang H. Unusual cerebral white matter change in a Chinese family with spinocerebellar ataxia type 12. J Neurol Sci. 2015 Feb 15;349(1–2):243–5. Louis ED, Pullman SL. Comparison of clinical vs. electrophysiological methods of diagnosing of essential tremor. Mov Disord. 2001 Jul;16(4):668–73. Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, et al. Management impact of imaging brain vesicular monoamine transporter type 2 in clinically uncertain Parkinsonian syndrome with 18F-AV133 and PET. J Nucl Med. 2017 Nov;58(11):1815–20. Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias: from genes to potential treatments. Nat Rev Neurosci. 2017 Oct;18(10):613–26. Holmes SE, Hearn EO, Ross CA, Margolis RL. SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia. Brain Res Bull. 2001 Oct–Nov 1;56(3–4):397–403. van Gaalen J, Giunti P, van de Warrenburg BP. Movement disorders in spinocerebellar ataxias. Mov Disord. 2011 Apr;26(5):792–800. Lu CS, Wu Chou YH, Yen TC, Tsai CH, Chen RS, Chang HC. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2. Mov Disord. 2002 Sep;17(5):1046–51. Wilder-Smith E, Tan EK, Law HY, Zhao Y, Ng I, Wong MC. Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci. 2003 Sep 15;213(1–2):25–8. Dürr A, Smadja D, Cancel G, Lezin A, Stevanin G, Mikol J, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain. 1995 Dec;118(Pt 6):1573–81. Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018 Apr;17(4):327–34. Holmes SE, O’Hearn E, Margolis RL. Why is SCA12 different from other SCAs? Cytogenet Genome Res. 2003;100(1–4):189–97. Latorre A, Del Gamba C, Menozzi E, Balint B, Brugger F, Bhatia KP. Abnormal DaTSCAN and atypical Parkinsonism in SCA12. Mov Disord Clin Pract. 2019 Mar 28;6(5):400–2. Zou J, Weng RH, Chen ZY, Wei XB, Wang R, Chen D, et al. Position emission tomography/single-photon emission tomography neuroimaging for detection of premotor Parkinson’s disease. CNS Neurosci Ther. 2016 Mar;22(3):167–77. Dürr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996 Apr;39(4):490–9. Wüllner U, Reimold M, Abele M, Bürk K, Minnerop M, Dohmen BM, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol. 2005 Aug;62(8):1280–5. O’Hearn EE, Hwang HS, Holmes SE, Rudnicki DD, Chung DW, Seixas AI, et al. Neuropathology and cellular pathogenesis of spinocerebellar ataxia type 12. Mov Disord. 2015 Nov;30(13):1813–24. Ackerman S. Discovering the brain. Washington, DC: National Academies Press (US); 1992. von Bieberstein L, van Niftrik CHB, Sebök M, El Amki M, Piccirelli M, Stippich C, et al. Crossed cerebellar diaschisis indicates hemodynamic compromise in ischemic stroke patients. Transl Stroke Res. 2021 Feb;12(1):39–48. Hou Y, Guo K, Fan X, Shang K, Wang J, Wang Z, et al. Crossed cerebellar diaschisis: risk factors and prognostic value in focal cortical dysplasia by 18F-FDG PET/CT. Ann Nucl Med. 2021 Jun;35(6):719–27. Agarwal A, Kaur H, Agarwal A, Nehra A, Pandey S, Garg A, et al. Cognitive impairment in spinocerebellar ataxia type 12. Parkinsonism Relat Disord. 2021 Apr;85:52–6. Kumada S, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, et al. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies. J Neuropathol Exp Neurol. 2002 Nov;61(11):984–91. Lin CH, Chen CM, Hou YT, Wu YR, Hsieh-Li HM, Su MT, et al. The CAG repeat in SCA12 functions as a cis element to up-regulate PPP2R2B expression. Hum Genet. 2010 Aug;128(2):205–12. Article / Publication Details

First-Page Preview

Received: December 08, 2021
Accepted: May 18, 2022
Published online: July 19, 2022

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.